Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients
Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients
This study is prospective randomized study which was performed in multicenter (General
 Hospital) in Korea. Inclusion criteria is patients who developed atrial
 fibrillation/flutter/tachycardia after pacemaker implantation among AF-pacemaker study
 (ClinicalTrials.gov Identifier: NCT03303872). The purpose is to investigate the recurrence
 rate of AF/AFL/AT in both groups after randomization for 60 months (5 years) in patients post
 pacemaker implantation and assess long term clinical results.
Inclusion Criteria:

 -  Patients who developed atrial fibrillation/flutter/tachycardia after pacemaker
 implantation among AF-pacemaker study (ClinicalTrials.gov Identifier: NCT03303872).

 -  Age: 18-80 years

 -  Patients eligible for the indications for permanent pacemaker implantation in
 accordance with 2016 revised Korean indication guideline on cardiac pacemaker
 implantation

 -  Estimated percentage of atrial pacing >40% under sinus rhythm (LR≥60bpm, close
 hysteresis and rest rate)

 -  Estimated percentage of ventricular pacing >40% under sinus rhythm (LR≥40bpm, DDD
 pacing, close hysteresis and rest rate)

 -  Patients who are willing to sign the informed consent.

 -  Patients who are willing to receive the implantation and post-operative follow-up.

 Exclusion Criteria:

 -  Persistent or permanent AF

 -  Severe hepatic and renal insufficiency (AST or ALT ≥ three times of normal upper
 limit; SCr > 3.5 mg/dl or Ccr < 30ml/min)

 -  Thyroid gland dysfunction

 -  Pregnancy

 -  Malignant tumor

 -  Severe organic heart disease (such as moderate to severe mitral regurgitation, severe
 valvular regurgitation and stenosis, dilated cardiomyopathy, hypertrophic
 cardiomyopathy, severe heart valve disease)

 -  Life expectancy < 12 months

 -  Patients unable or unwilling to cooperate in the study procedures.